1,241 filings
Page 2 of 63
6-K
xg2dyyqn
27 Oct 23
Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
12:39pm
6-K
brgbudk
27 Oct 23
Sanofi Enters Next Chapter of Play to Win Strategy
11:33am
6-K
uku0s
26 Oct 23
Sanofi and Regeneron provide update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
7:16am
6-K
f09pdw
20 Oct 23
Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
2:31pm
6-K
yd1sjgrbzxrqsaf2sq
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
51712frhojc80pr
27 Sep 23
Current report (foreign)
6:06am
6-K
m7ex6oo8qcm508tgkeh
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
uepy4phww9csiunnh
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
67st 6zf3qzk
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
2m8s4v mrdf7f
28 Jul 23
Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
9:18am
6-K
1dp6usqwwuihl3y
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
lv1nrkcq
24 Jul 23
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
12:43pm
6-K
o7c0k cw9r8
5 Jul 23
Current report (foreign)
8:43am
11-K
9aaa tfcwjdnxsfs
28 Jun 23
Annual report of employee stock purchases
2:32pm
11-K
0v7jqhp7oe
28 Jun 23
Annual report of employee stock purchases
2:31pm
6-K
gk3yantn4ama2yg5zina
20 Jun 23
Current report (foreign)
10:18am
6-K
zjx0cmybm246 7pwdq
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
SD
6ms9qpcb7iupuhwwz
30 May 23
Conflict minerals disclosure
11:15am
6-K
6pkst6j qpbt5a
23 May 23
Current report (foreign)
1:01pm
6-K
e4j1m
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am